Marshall Wace’s Apogee Therapeutics APGE Stock Holding History

Marshall Wace’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.3M	Sell	77,475 -2,726	-3%	-$246K	0.01%	1026
2026 Q1	$6.75M	Buy	80,201 +29,457	+58%	+$2.14M	0.01%	1155
2025 Q4	$3.83M	Buy	50,744 +43,717	+622%	+$2.75M	﹤0.01%	1273
2025 Q3	$279K	Sell	7,027 -83,541	-92%	-$3.19M	﹤0.01%	2457
2025 Q2	$3.93M	Buy	90,568 +78,969	+681%	+$3M	﹤0.01%	1266
2025 Q1	$433K	Sell	11,599 -64,250	-85%	-$2.48M	﹤0.01%	2134
2024 Q4	$3.44M	Buy	75,849 +72,174	+1,964%	+$3.68M	﹤0.01%	1229
2024 Q3	$216K	Sell	3,675 -78,271	-96%	-$3.75M	﹤0.01%	2274
2024 Q2	$3.22M	Buy	+81,946	New	+$3.98M	﹤0.01%	1168

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Marshall Wace's APGE Position: Q2 2026 in Review

Marshall Wace reduced its Apogee Therapeutics (APGE) stake by 3.4% in Q2 2026, selling an estimated $246K and leaving 77,475 shares worth $10.3M. The position accounts for 0.01% of the portfolio, ranked #1026.

Marshall Wace first reported a position in APGE in Q2 2024 and has held it in 9 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Marshall Wace held 77,475 shares of Apogee Therapeutics worth $10.3M as of Q2 2026.
Marshall Wace sold 2,726 Apogee Therapeutics shares in Q2 2026, an estimated $246K.
Apogee Therapeutics made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1026 holding.
Marshall Wace first reported a position in Apogee Therapeutics in Q2 2024 and has held it in 9 quarters since.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.